Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The investigators intend to evaluate the safety and toxicity profile of intravesically
administered multidrug regimen of Cabazitaxel, Cisplatin and Gemcitabine in treatment
refractory Transitional Cell Carcinoma.The investigators propose to conduct a combined phase
I trial to assess the safety, toxicity, and efficacy of a novel multidrug intravesical regimen
consisting of Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the treatment of BCG resistant
non-muscle invasive urothelial carcinoma of the bladder. This phase I trial will have a
combined dose and cycle-escalation scheme with enrollment of up to 24 patients.